Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | HPGD | P15428 | 1/20 | 0.31 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.31 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.31 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.31 |
| ▸ | ACHE | P22303 | 1/20 | 0.31 |
| ▸ | RXRA | P19793 | 2/20 | 0.30 |
| ▸ | RXRB | P28702 | 2/20 | 0.30 |
| ▸ | RXRG | P48443 | 1/20 | 0.30 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.30 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14054015 | 0.81 | ATM (0.30) | — | |
| SCHEMBL954706 | 0.79 | ALDH1A1 (0.34) | ALDH1A1HPGDALOX15HSD17B10TDP1 | |
| SCHEMBL5477987 | 0.78 | ALDH1A1 (0.34) | ALDH1A1HPGDALOX15HSD17B10TDP1 | |
| SCHEMBL27660860 | 0.74 | KDM4E (0.33) | HSD17B10RXRACYP1A2CYP2C19 | |
| SCHEMBL6851963 | 0.74 | — | — | |
| SCHEMBL5957942 | 0.71 | ALDH1A1 (0.34) | ALDH1A1HPGDALOX15HSD17B10TDP1 | |
| SCHEMBL4027510 | 0.70 | NR1I2 (0.35) | ALDH1A1HPGDALOX15HSD17B10TDP1 | |
| SCHEMBL7196050 | 0.70 | NR1I2 (0.32) | ALDH1A1HPGDALOX15HSD17B10TDP1 | |
| SCHEMBL15067852 | 0.69 | ALDH1A1 (0.39) | ALDH1A1HPGDALOX15HSD17B10TDP1 | |
| SCHEMBL2869063 | 0.67 | TSHR (0.39) | ALDH1A1HPGDALOX15HSD17B10TDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 33 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6509426-B2 | Dichloro(1,1'-dimethylsilylenebis(2-methyl-4-(4-methoxyphenyl) -4H-azulenyl))zirconium, for example; can produce polyolefin with high molecular weight and high melting point for extrusion or injection moldability | JAPAN POLYCHEM CORPORATION (JP) | 2003-01-21 | — | — | US | claimed |
| US-5294737-A | Hydrolysis, cyclization, condensation | THE RESEARCH FOUNDATION STATE UNIVERSITY OF NEW YORK (US) | 1994-03-15 | — | — | US | claimed |
| WO-2024009732-A1 | POSITIVE-ACTING PHOTOSENSITIVE RESIN COMPOSITION | 日本ポリテック株式会社 | 2024-01-11 | — | — | WO | disclosed |
| WO-2023080254-A1 | POSITIVE-ACTING PHOTOSENSITIVE RESIN COMPOSITION | 株式会社レゾナック | 2023-05-11 | — | — | WO | disclosed |
| CN-115043810-A | Method for preparing chiral carbon-hydrogen bond oxidation product by non-metal catalyzed asymmetric carbon-hydrogen bond oxidation | 浙江大学 | 2022-09-13 | — | — | CN | disclosed |
| CN-114075150-A | Method for preparing chiral amino alcohol derivative through nonmetal-catalyzed asymmetric carbon-hydrogen bond amination | 浙江大学 | 2022-02-22 | — | — | CN | disclosed |
| EP-1805170-B1 | MIF-INHIBITORS | NOVARTIS AG (CH) | 2010-04-14 | — | — | EP | disclosed |
| US-7378416-B2 | MIF-inhibitors | NOVARTIS AG (CH) | 2008-05-27 | — | — | US | disclosed |
| US-20070219189-A1 | MIF-INHIBITORS | NOVARTIS AG (CH) | 2007-09-20 | — | — | US | disclosed |
| EP-1805170-A1 | MIF-INHIBITORS | Novartis AG (CH) | 2007-07-11 | — | — | EP | disclosed |
| EP-1620392-B1 | HYDROXY-BIPHENYL-CARBALDEHYDE OXIME DERIVATIVES AND THEIR USE AS ESTROGENIC AGENTS | WYETH CORP (US) | 2007-06-27 | — | — | EP | disclosed |
| EP-0755457-A4 | NOVEL ARYL-N-ALKYLACRIDANTHIOCARBOXYLATE DERIVATIVES USEFUL FOR CHEMILUMINESCENT DETECTION | LUMIGEN INC (US) | 1997-07-16 | — | — | EP | disclosed |
| EP-0755457-A1 | NOVEL ARYL-N-ALKYLACRIDANTHIOCARBOXYLATE DERIVATIVES USEFUL FOR CHEMILUMINESCENT DETECTION | LUMIGEN, INC. (US) | 1997-01-29 | — | — | EP | disclosed |
| WO-1995028495-A1 | NOVEL ARYL-N-ALKYLACRIDANTHIOCARBOXYLATE DERIVATIVES USEFUL FOR CHEMILUMINESCENT DETECTION | LUMIGEN, INC. (US) | 1995-10-26 | — | — | WO | disclosed |
| US-5318876-A | Solutions of water insoluble, base soluble polymeric binder, substituted sulfonium salts, substituted benzenesulfonates, having tolerance for delay between exposure and heating to develop | BASF AKTIENGESELLSCHAFT (DE) | 1994-06-07 | — | — | US | disclosed |
| US-5300400-A | Process for the production of relief patterns and images utilizing an organic compound having at least one acid-cleavable group and a storage stability improving amount of a second organic compound | BASF AKTIENGESELLSCHAFT (DE) | 1994-04-05 | — | — | US | disclosed |
| US-5191124-A | Photoinitiators for Cationic Polymerization | BASF AKTIENGESELLSCHAFT (DE) | 1993-03-02 | — | — | US | disclosed |
| US-5069998-A | RADIATION SENSITIVE MIXTURE AND PRODUCTION OF RELIEF PATTERNS | BASF AKTIENGESELLSCHAFT (DE) | 1991-12-03 | — | — | US | disclosed |
| US-5064746-A | RADIATION-SENSITIVE MIXTURE FOR PHOTOSENSITIVE COATING MATERIALS AND THE PRODUCTION OF RELIEF PATTERNS AND RELIEF IMAGES | BASF AKTIENGESELLSCHAFT (DE) | 1991-11-12 | — | — | US | disclosed |
| US-4883740-A | RELIEF PATTERNS AND IMAGES | BASF AKTIENGESELLSCHAFT (DE) | 1989-11-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070219189-A1 | MIF-INHIBITORS | MIF, FOXM1, CCR8 | ALDH1A1 415/4885HPGD 2087/4885ALOX15 1313/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.